Skip to main content
SpringerLink
Log in

Gepirone in Depression and Anxiety Disorders

An Initial Appraisal of its Clinical Potential

  • Drug Evaluation
  • Published:
CNS Drugs Aims and scope Submit manuscript

Summary

Gepirone is an azapirone derivative with partial agonist activity at the post-synaptic serotonin (5-hydroxytryptamine) 5-HT1A receptor. In contrast to buspirone, gepirone lacks appreciable in vitro affinity for the dopamine D2 receptor, and exhibits only limited dopaminergic activity in vivo. The drug is active in several animal models considered predictive of antidepressant and anxiolytic activity, and is currently under development as a potential treatment for affective and anxiety disorders. The limited number of controlled clinical trials performed to date indicate that gepirone is of superior therapeutic efficacy to placebo on short term (≤ 10 weeks) administration to outpatients with generalised anxiety disorder (dosage range ≤ 60 mg/day) and major depressive disorder or atypical depression (dosage range ≤ 90 mg/day). The antidepressant effect of gepirone appears to be additional to its anxiolytic effect. As with buspirone, onset of the anxiolytic effect of gepirone appears to be delayed (≈ 2 to 4 weeks) relative to that of the benzodiazepines. The tolerability profile of gepirone mirrors that of buspirone: gepirone is nonsedating, lacks anticholinergic effects, and appears to be of low abuse potential. Gepirone has a possible role in the treatment of major depression, particularly that of the milder, non-endogenous or non-melancholic subtype, major depression associated with generalised anxiety, atypical depression, and chronic generalised anxiety disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hamon M, Fattaccini CM, Adrien J, et al. Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine1A agonists with potential anxiolytic prioperties. J Pharmacol Exp Ther 1988; 246: 745–52

    PubMed  CAS  Google Scholar 

  2. Yocca FD. Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT1A receptors. J Clin Psychopharmacol 1990; 10: 6S–12S

    Article  PubMed  CAS  Google Scholar 

  3. Eison AS, Eison MS, Stanley M, et al. Serotonergic mechanisms in the behavioral effects of buspirone and gepirone. Pharmacol Biochem Behav 1986; 24: 701–7

    Article  PubMed  CAS  Google Scholar 

  4. McMillen BA, Scott SM, Williams HL, et al. Effects of gepirone, an aryl-piperazine anxiolytic drug, on aggressive behavior and brain monoaminergic neurotransmission. Naunyn Schmiedebergs Arch Pharmacol 1987; 335: 454–64

    Article  PubMed  CAS  Google Scholar 

  5. Van Wijngaarden IV, Tulp MTM, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 1990; 188: 301–12

    Article  PubMed  Google Scholar 

  6. Bennett JE, Matheson GK. Autoradiographic localisation of [3H]gepirone in the rat brain [abstract]. FASEB J 1990; 4: A617

    Google Scholar 

  7. Blier P, de Montigny C. Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1987; 1: 470–80

    Article  PubMed  CAS  Google Scholar 

  8. Robinson DS, Alms DR, Shrotriya RC, et al. Serotonergic anxiolytics and treatment of depression. Psychopathology 1989; 22 (Suppl. 1): 27–36

    Article  PubMed  Google Scholar 

  9. Bohmaker K, Eison AS, Yocca FD, et al. Comparative effects of chronic 8-OH-DPAT, gepirone and ipsapirone treatment on the sensitivity of somatodendritic 5-HT1Aautoreceptors. Neuropharmacol 1993; 32: 527–34

    Article  CAS  Google Scholar 

  10. Wellner SA, de Montigny C, Desjardins P, et al. Autoradiographic quantification of serotonin1A receptors in rat brain following antidepressant treatment. Synapse 1989; 4: 347–52

    Article  Google Scholar 

  11. Yocca FD, Eison AS, Hyslop DK, et al. Unique modulation of central 5-HT2 receptor binding sites and 5-HT2 receptor-mediated behavior by continuous gepirone treatment. Life Sci 1991; 49: 1777–85

    Article  PubMed  CAS  Google Scholar 

  12. Eison AS, Yocca FD. Reduction in cortical 5-HT2 receptor sensitivity after continuous gepirone treatment. Eur J Pharmacol 1985; 111: 389–92

    Article  PubMed  CAS  Google Scholar 

  13. Peroutka SJ, Snyder SH. Long-term antidepressant treatment decreases spiroperidol-labelled serotonin receptor binding. Science 1980; 210: 88–90

    Article  PubMed  CAS  Google Scholar 

  14. Sinton CM, Fallon SL. Electrophysiological evidence for a functional differentiation between subtypes of the 5-HT1 receptor. Eur J Pharmacol 1988; 157: 173–81

    Article  PubMed  CAS  Google Scholar 

  15. Sharp T, Bramwell SR, Grahame-Smith DG. 5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol 1989; 96: 283–90

    Article  PubMed  CAS  Google Scholar 

  16. Sanghera MK, German DC. The effect of benzodiazepine and non-benzodiazepine anxiolytics on locus coeruleus unit activity. J Neural Transm 1983; 57: 267–79

    Article  PubMed  CAS  Google Scholar 

  17. Rimele TJ, Henry DE, Lee DK, et al. Tissue-dependent alpha adrenoceptor activity of buspirone and related compounds. J Pharmacol Exp Ther 1987; 241: 771–8

    PubMed  CAS  Google Scholar 

  18. Bianchi G, Caccia S, Delia Vedova F, et al. The α2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyridinyl)-piperazine (PmP). Eur J Pharmacol 1988; 151: 365–71

    Article  PubMed  CAS  Google Scholar 

  19. Giral P, Soubrie P, Puech AJ. Pharmacological evidence for the involvement of 1-(2-pyridinyl)-piperazine (1-PmP) in the interaction of buspirone or gepirone with noradrenergic systems. Eur J Pharmacol 1987; 134: 113–6

    Article  PubMed  CAS  Google Scholar 

  20. Nash JF, Meltzer HY. Effect of gepirone and ipsapirone on the stimulated and unstimulated secretion of prolactin in the rat. J Pharmacol Exp Ther 1989; 249: 236–41

    PubMed  CAS  Google Scholar 

  21. Fletcher PJ, Davis M. The involvement of 5-hydroxytryptaminergic and dopaminergic mechanisms in the eating induced by buspirone, gepirone and ipsapirone. Br J Pharmacol 1990; 99: 519–25

    Article  PubMed  CAS  Google Scholar 

  22. Yocca FD, Wright RN, Margraf RR, et al. 8-OH-DPAT and buspirone analogs inhibit the ketanserin-specific quipazine-induced head shake response in rats. Pharmacol Biochem Behav 1990; 35: 251–4

    Article  PubMed  CAS  Google Scholar 

  23. Gilbert F, Dourish CT. Effects of the novel anxiolytics gepirone, buspirone and ipsapirone on free feeding and on feeding induced by 8-OH-DPAT. Psychopharmacology 1987; 93: 349–52

    Article  PubMed  CAS  Google Scholar 

  24. Dourish CT, Hutson PH, Kennett GH, et al. 8-OH-DPAT-induced hyperphagia: its neural basis and possible therapeutic relevance. Appetite 1986; 7 (Suppl.): 127–40

    Article  PubMed  CAS  Google Scholar 

  25. Giral P, Martin P, Soubrie P, et al. Reversal of helpless behavior in rats by putative 5-HT1A agonists. Biol Psychiatry 1988; 23: 237–42

    Article  PubMed  CAS  Google Scholar 

  26. Martin P. Serotonergic systems and depression: approach through the learned helplessness paradigm. In: Macher JP, Crocq MA, editors. New prospects in psychiatry: the bioclinical interface. Amsterdam: Elsevier, 1992: Vol. 9, 346–62

    Google Scholar 

  27. Chojnacka-Wojcik E, Tatarczynska E, Golembiowska K, et al. Involvement of 5-HT1A receptors in the antidepressant-like activity of gepirone in the forced swimming test in rats. Neuropharmacology 1991; 30: 711–17

    Article  PubMed  CAS  Google Scholar 

  28. Przegalinski E, Tatarczynska E, Chojnacka-Wojcik E. Antidepressant-like activity of ipsapirone, buspirone and gepirone in the forced swimming test in rats pretreated with proadifen. J Psychopharmacol 1990; 4: 204–9

    Article  PubMed  CAS  Google Scholar 

  29. Wieland S, Lucki I. Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test. Psychopharmacology 1990; 101: 497–504

    Article  PubMed  CAS  Google Scholar 

  30. Hand TH, Marek GJ, Jolly D, et al. Antidepressant-like effect of the 5-HT1A agonists buspirone, gepirone, 8-OH-DPAT, 5-MeODMT in rats on the DRL 72-s schedule: differential blockade by methysergide and purported 5-HT1A agonists [abstract]. Soc Neurosci Abstr 1989; 15: 1282

    Google Scholar 

  31. Richards JB, Sabol KS, Jolly DC, et al. Differential effects of 5HT1A agonists 8OHDPAT, buspirone, gepirone, ipsapirone and 5MEODMT on a DRL 72 sec schedule of reinforcement [abstract]. Soc Neurosci Abstr 1990; 16: 752

    Google Scholar 

  32. Lucki I. Behavioral studies of serotonin receptor agonists as antidepressant drugs. J Clin Psychiatry 1991; 52 (Suppl. 12): 24–31

    PubMed  Google Scholar 

  33. Costello NL, Carlson JN, Glick SD, et al. The effects of acute administration of gepirone in rats trained on conflict schedules having different degrees of predictability. Pharmacol Biochem Behav 1991; 40: 795–800

    Article  PubMed  CAS  Google Scholar 

  34. Stefanski R, Palejko W, Kostowski W, et al. The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety. Neuropharmacology 1992; 31: 1251–8

    Article  PubMed  CAS  Google Scholar 

  35. Young R, Urbancic A, Emrey TA, et al. Behavioral effects of several new anxiolytics and putative anxiolytics. Eur J Pharmacol 1987; 143: 361–71

    Article  PubMed  CAS  Google Scholar 

  36. Barrett JE, Witkin JM, Mansbach RS, et al. Behavioural studies with anxiolytic drugs. III. Antipunishment actions of buspirone in the pigeon do not involve benzodiazepine receptor mechanisms. J Pharmacol Exp Ther 1986; 238: 1009–13

    PubMed  CAS  Google Scholar 

  37. Bodnoff SR, Suranyi-Cadotte B, Quirion R, et al. A comparison of the effects of diazepam versus several typical and atypical anti-depressant drugs in an animal model of anxiety. Psychopharmacology 1989; 97: 277–9

    Article  PubMed  CAS  Google Scholar 

  38. Dunn RW, Corbett R, Fielding S. Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur J Pharmacol 1989; 169: 1–10

    Article  PubMed  CAS  Google Scholar 

  39. Kehne JH, Cassella JV, Davis M. Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm. Psychopharmacology 1988; 94: 8–13

    Article  PubMed  CAS  Google Scholar 

  40. Mansbach RS, Geyer MA. Blockade of potentiated startle responding in rats by 5-hydroxytryptamine1A receptor ligands. Eur J Pharmacol 1988; 156: 375–83

    Article  PubMed  CAS  Google Scholar 

  41. Blanchard RJ, Yudko EB, Blanchard C, et al. High frequency (35–70 kHz) ultrasonic vocalizations in rats confronted with anesthetized conspecifics: effects of gepirone, ethanol, and diazepam. Pharmacol Biochem Behav 1993; 44: 313–19

    Article  PubMed  CAS  Google Scholar 

  42. Vivian JA, Miczek KA. Diazepam and gepirone selectively attenuate either 20–32 or 32–64 kHz ultrasonic vocalizations during aggressive encounters. Psychopharmacology 1993; 112: 66–73

    Article  PubMed  CAS  Google Scholar 

  43. Goudie AJ, Leathley MJ. Effects of the 5HT1A agonist anxiolytic gepirone on benzodiazepine withdrawal signs in rats. Behav Pharmacol 1991; 2: 461–9

    Article  PubMed  Google Scholar 

  44. Balster RL. Abuse potential of buspirone and related drugs. J Clin Psychopharmacol 1990; 10: 31S–37S

    Article  PubMed  CAS  Google Scholar 

  45. Anderson IM, Cowen PJ, Grahame-Smith DG. The effects of gepirone on neuroendocrine function and temperature in humans. Psychopharmacology 1990; 100: 498–503

    Article  PubMed  CAS  Google Scholar 

  46. Rausch JL, Stahl SM, Hauger RL. Cortisol and growth hormone responses to the 5-HT1A agonist gepirone in depressed patients. Biol Psychiatry 1990; 28: 73–8

    Article  PubMed  CAS  Google Scholar 

  47. Cowen PJ, Anderson IM, Grahame-Smith DG. Neuroendocrine effects of azapirones. J Clin Psychopharmacol 1990; 10: 21S–25S

    Article  PubMed  CAS  Google Scholar 

  48. Tay LK, Dixon F, Sostrin MB, et al. The site of gastrointestinal absorption of gepirone in humans. J Clin Pharmacol 1992; 32: 827–32

    PubMed  CAS  Google Scholar 

  49. Tay LK, Sciacca MA, Sostrin MB, et al. Effect of food on the bioavailability of gepirone in humans. J Clin Pharmacol 1993; 33: 631–35

    PubMed  CAS  Google Scholar 

  50. Tay LK, Farmen RH, Pittman KA. Pharmacokinetics and disposition of gepirone and 1-pyrimidinylpiperazine (1-PP) in humans after intravenous and oral administration of 14C-gepirone [abstract]. Pharm Res 1990; 7 (Suppl. 9): S–208

    Google Scholar 

  51. Gammans RE, Mayol RF, Labudde JA. Metabolism and disposition of buspirone. Am J Med 1986; 80 (Suppl. 3B): 41–51

    Article  PubMed  CAS  Google Scholar 

  52. Caccia S, Fong MH, Guiso G. Disposition of the psychotropic drugs buspirone, MJ-13805 and piribedil, and of their common active metabolite 1-(2-pyrimidinyl)-piperazine in the rat. Xenobiotica 1985; 15: 835–44

    Article  PubMed  CAS  Google Scholar 

  53. Chignon JM, Lepine JP. Panic and hypertension associated with single dose of buspirone. Lancet 1989; 2: 46–7

    Article  PubMed  CAS  Google Scholar 

  54. Eison AS. Serotonin: a common neurobiologic substrate in anxiety and depression. J Clin Psychopharmacol 1990; 10: 26S–30S

    Article  PubMed  CAS  Google Scholar 

  55. Rickels K. Buspirone in clinical practice. J Clin Psychiatry 1990; 51 (Suppl. 9): 51–4

    PubMed  Google Scholar 

  56. Rickeis KR, Amsterdam JD, Clary C, et al. Buspirone in depressed outpatients: a controlled study. Psychopharmacol Bull 1990; 26: 163–7

    Google Scholar 

  57. Rickels KR, Amsterdam JD, Clary C, et al. Buspirone in major depression: a controlled study. J Clin Psychiatry 1991; 52: 34–8

    PubMed  CAS  Google Scholar 

  58. Robinson DS, Rickels KR, Feighner J, et al. Clinical effects of 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990; 10: 67S–76S

    Article  PubMed  CAS  Google Scholar 

  59. Jenkins SW, Robinson DS, Fabre LF, et al. Gepirone in the treatment of major depression. J Clin Psychopharmacol 1990; 10 (Suppl.): 77S–85S

    Article  PubMed  CAS  Google Scholar 

  60. Harto NE, Branconnier RJ, Spera KP, et al. Clinical profile of gepirone, a nonbenzodiazepine anxiolytic. Psychopharmacol Bull 1988; 24: 154–60

    PubMed  CAS  Google Scholar 

  61. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed. Washington, DC: American Psychiatric Association, 1980

  62. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria (RDC) for a selected group of functional disorders, 3rd ed. New York, Biometrics Research, 1977

    Google Scholar 

  63. Rausch JL, Ruegg R, Moeller FG. Gepirone as a 5-HT1A agonist in the treatment of major depression. Psychopharmacol Bull 1990; 26: 169–71

    PubMed  CAS  Google Scholar 

  64. Amsterdam JD. Gepirone, a selective serotonin (5HT1A) partial agonist in the treatment of major depression. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 271–80

    Article  PubMed  CAS  Google Scholar 

  65. Csanalosi I, Schweizer E, Case WG, et al. Gepirone in anxiety: a pilot study. J Clin Psychopharmacol 1987; 7: 31–3

    Article  PubMed  CAS  Google Scholar 

  66. Pecknold JC, Luthe L, Scott-Fleury MH, et al. Gepirone and the treatment of panic disorder: an open study. J Clin Psychopharmacol 1993; 13: 145–9

    Article  PubMed  CAS  Google Scholar 

  67. Lader M. Psychological effects of buspirone. J Clin Psychiatry 1982; 43 (Section 2): 62–7

    PubMed  CAS  Google Scholar 

  68. Paul SM. Anxiety and depression: a common neurobiological substrate? J Clin Psychiatry 1988; 49 (Suppl. 10): 13–6

    PubMed  Google Scholar 

  69. Stavrakaki C, Vargo B. The relationship of anxiety and depression: a review of the literature. Br J Psychiatry 1986; 149: 7–16

    Article  PubMed  CAS  Google Scholar 

  70. Warner MD, Peabody CA, Whiteford HA, et al. Alprazolam as an antidepressant. J Clin Psychiatry 1988; 49: 148–50

    PubMed  CAS  Google Scholar 

  71. Dunner D, Myers J, Khan A, et al. Adinazolam- a new antidepressant: findings of placebo-controlled, double-blind study in outpatients with major depression. J Clin Psychopharmacol 1987; 7: 170–2

    Article  PubMed  CAS  Google Scholar 

  72. Liebowitz MR, Fyer AJ, Gorman JM, et al. Tricyclic therapy of the DSM-III anxiety disorders: a review with implications for further research. J Psychiatr Res 1988; 22 (Suppl. 1): 7–31, 1988

    Article  PubMed  Google Scholar 

  73. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50: 884–95

    Article  PubMed  CAS  Google Scholar 

  74. Sussman N. How to manage anxious patients who are depressed. J Clin Psychiatry 1993; 54 (Suppl. 5): 8–16

    PubMed  Google Scholar 

  75. Fabre LF. Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatry 1990; 51 (Suppl. 9): 55–61

    PubMed  Google Scholar 

  76. Eison AS, Temple DL. Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am J Med 1986; 80 (Suppl. 3B): 1–9

    Article  PubMed  CAS  Google Scholar 

  77. New JS. The discovery and development of buspirone: a new approach to the treatment of anxiety. Med Res Rev 1990; 101: 283–326

    Article  Google Scholar 

  78. Dubovsky SL. Generalized anxiety disorder: new concepts and psychopharmacologic therapies. J Clin Psychiatry 1990; 51 (Suppl. 1): 3–10

    Google Scholar 

  79. Goa KL, Ward A. Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986; 32: 114–29

    Article  PubMed  CAS  Google Scholar 

  80. Rickels K, Case WG, Chung H, et al. Diazepam and halazepam in anxiety: some prognostic indicators. Int Pharmacopsychiatr 1978; 13: 118–25

    CAS  Google Scholar 

  81. Schweizer E, Rickels K, Lucki I. Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use. N Engl J Med 1986; 314: 719–20

    Article  PubMed  CAS  Google Scholar 

  82. Ballenger JC, Burrows G, DuPont RL, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short term treatment. Arch Gen Psychiatry 1988; 45: 413–22

    Article  PubMed  CAS  Google Scholar 

  83. Gorman JM, Liebowitz MR, Fyer AJ. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987; 7: 329–32

    Article  PubMed  CAS  Google Scholar 

  84. Pohl R, Balon R, Yeragani VK. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 1989; 22 (Suppl.): 60–9

    Article  PubMed  Google Scholar 

  85. Sheehan DV, Raj AB, Sheehan KH, et al. Is buspirone effective for panic disorder? J Clin Psychopharmacol 1990; 10: 3–11

    Article  PubMed  CAS  Google Scholar 

  86. Cross National Collaborative Panic Study Second Phase. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine and placebo. Br J Psychiatry 1992; 160: 191–205

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Andrew Fitton & Paul Benfield

Authors
  1. Andrew Fitton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Benfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Various sections of the manuscript reviewed by: P. Bech, Psychiatric Institute, Frederiksborg General Hospital, Hillerød, Denmark; S.L. Dubovsky, Departments of Psychiatry and Medicine, University of Colorado School of Medicine, Denver, Colorado, USA; F. Haffner, Psychiatric Institute, Frederiksborg General Hospital, Hillerød, Denmark; I. Lucki, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA; P.Martin, Département de Pharmacologie, Faculté de Médecine Pitié-Salpêtrière, Paris, France; J.C. Pecknold, Douglas Hospital Research Centre, Montreal, Quebec, Canada; K. Rickels, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fitton, A., Benfield, P. Gepirone in Depression and Anxiety Disorders. CNS Drugs 1, 388–398 (1994). https://doi.org/10.2165/00023210-199401050-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199401050-00009

Keywords

Search

Navigation